GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Bangkok Genomics Innovation PCL BKGI.BK · THB

N/A · SET · 🇹🇭 Thailand

Compare

2.30

0.00%

Close of 9 Nov 2026, in THB

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Bangkok Genomics Innovation PCL

Its shares trade on SET under the ticker BKGI.BK. It has been listed since 20 March 2024. In the fiscal year to 31 December 2025, it reported revenue of THB 379.5m and net income of THB 45.3m. At that date it held total assets of THB 701.9m and shareholders' equity of THB 551.2m.

Bangkok Genomics Innovation PCL is a TH-based company operating in industry. The company is headquartered in Bangkok, Bangkok Metropolis. The company went IPO on 2024-03-20. Bangkok Genomics Innovation Public Company Limited is a Thailand-based company. The firm operates as a research and application center for genomics and bioinformatics. The firm is engaged in offering the NIFTY test, and clinical and genomics services. The company provides technological development of precision medicine. Its services include COVID-19 RT-PCR Testing, BGI VISTA Carrier Screening, BGI NOVA Newborn Genetic Screening, BGI SENTIS Hereditary Cancer Screening, BGI’s Clinical Whole Exome Sequencing, and COLOTECT 3.0 Non-invasive Test for Colorectal Cancer Screening. The company operates offices and laboratories across North America, Europe, and Asia-Pacific.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
N/A
Industry
N/A
Listed since
20 Mar 2024

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Bangkok Genomics Innovation PCL offers NIFTY test and clinical genomics services in Thailand.
  • The company operates laboratories across North America, Europe, and Asia-Pacific regions.
  • Bangkok Genomics Innovation PCL provides precision medicine technological development for healthcare applications.

Weaknesses

  • The company's IPO listing date is 20 March 2024, which is recent.
  • Bangkok Genomics Innovation PCL has no offices in South America or Africa.
  • The company's services include limited genetic screening options for rare diseases.

Opportunities

  • Bangkok Genomics Innovation PCL can expand its NIFTY test services in the Asia-Pacific market.
  • The company can leverage its BGI VISTA Carrier Screening in European markets.
  • Bangkok Genomics Innovation PCL can grow its COLOTECT 3.0 Non-invasive Test for colorectal cancer screening.

Threats

  • The company faces competition from established genomics firms in North America.
  • Bangkok Genomics Innovation PCL must comply with varying healthcare regulations across Europe.
  • The company's reliance on BGI products may limit its independent innovation.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.